DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Mounjaro is tirzepatide approved for type 2 diabetes (off-label for weight loss).
The strongest diabetes injectable, if you have type 2 diabetes
For adults with type 2 diabetes, Mounjaro is one of the most effective glucose-lowering medications available, and a head-to-head trial (SURPASS-2) showed it outperformed injectable semaglutide on both blood sugar and weight. The catch: it is FDA-approved only for diabetes, so insurance coverage for off-label weight loss is increasingly denied. If weight loss is your goal and you don't have diabetes, Lilly's Zepbound (the same drug, tirzepatide) is the on-label option. Whether it is right for you is a decision to make with your prescriber.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. The FDA approved it on May 13, 2022 as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults with type 2 diabetes mellitus (FDA). It is delivered as a once-weekly subcutaneous (under-the-skin) injection.
Two limitations are written directly into the label. Mounjaro is not indicated for type 1 diabetes, and it has not been studied in people with a history of pancreatitis (FDA label, 2022). It is also not a primary insulin replacement.
A point of frequent confusion: tirzepatide is sold under two different brand names for two different uses. Mounjaro is approved for type 2 diabetes. Zepbound — the identical molecule — was approved by the FDA on November 8, 2023 for chronic weight management, and later for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA). They are the same drug; the brand depends on the approved indication and how insurance categorizes the prescription. Importantly, weight loss is not an on-label use of Mounjaro itself — when clinicians prescribe tirzepatide specifically for obesity, the on-label product is Zepbound.
Mounjaro is the first dual GIP and GLP-1 receptor agonist (FDA). GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are two "incretin" hormones the gut releases after eating. Older drugs in this space — semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity), liraglutide — act on the GLP-1 receptor alone. Tirzepatide activates both.
Through these receptors it works in several complementary ways:
The GIP component is what distinguishes tirzepatide. The prevailing scientific view is that adding GIP-receptor activity on top of GLP-1 amplifies the metabolic effect, which helps explain why tirzepatide outperformed a GLP-1-only drug head-to-head (see below). The exact contribution of GIP signaling is still an area of active research.
The evidence here is unusually strong, drawn from the large Phase 3 SURPASS program.
In SURPASS-2, published in the *New England Journal of Medicine* in 2021, 1,879 adults with type 2 diabetes on metformin were randomized to tirzepatide 5 mg, 10 mg, or 15 mg, or to injectable semaglutide 1 mg (a real-world active comparator, not placebo) over 40 weeks (NEJM 2021). All three tirzepatide doses produced statistically superior A1C reductions versus semaglutide 1 mg, with the 15 mg dose achieving about a 2.3 percentage-point drop in A1C (from a mean baseline near 8.3%) and a treatment difference of roughly -0.45% over semaglutide. On the 15 mg dose about 86% of patients reached an A1C below 7% (the standard treatment target), and roughly half reached the non-diabetic range below 5.7% (NEJM 2021).
That last point matters for interpretation: the comparator was semaglutide 1 mg — the diabetes dose at the time — not the 2.4 mg dose later used for weight loss (Wegovy). So SURPASS-2 demonstrates tirzepatide's superiority within the diabetes treatment landscape, not against semaglutide's maximum dose.
Although weight loss is not the on-label use of Mounjaro, it is a consistent secondary finding. In SURPASS-2, the 15 mg dose produced roughly 11–12% body-weight reduction (about 11.2 kg), nearly double the weight loss seen with semaglutide 1 mg (NEJM 2021). The dedicated obesity trials of the same molecule (SURMOUNT-1, conducted in adults without diabetes for what became Zepbound) showed mean reductions of about 20% at the highest dose over 72 weeks (NEJM 2022) — among the largest seen with any non-surgical therapy.
For years the open question was whether tirzepatide's metabolic wins translated into fewer heart attacks and strokes. SURPASS-CVOT, a roughly 13,300-patient head-to-head trial against dulaglutide (an established GLP-1 with proven cardiovascular benefit), reported results in 2025. Over a median of about four years, the primary composite of cardiovascular death, heart attack, or stroke occurred in 12.2% of tirzepatide patients versus 13.1% on dulaglutide (hazard ratio ≈ 0.92, 95.3% CI roughly 0.83–1.01). This met the prespecified bar for non-inferiority but did not reach statistical superiority for the primary endpoint (NEJM 2025; presented at ADA 2025). Tirzepatide was superior on several secondary measures, including A1C, weight, and all-cause mortality. The practical takeaway: tirzepatide delivers cardiovascular protection at least on par with a GLP-1 drug already known to be heart-protective — important reassurance for the high-risk diabetes population, even if outright superiority over dulaglutide was not proven.
Honest limitations of the evidence: most pivotal trials ran 40–72 weeks, so very-long-term data are still accumulating. SURPASS-2 used an active comparator at less than its maximum dose. And trial populations are more closely monitored than real-world patients, where adherence and dose titration are often messier.
Mounjaro comes in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg, injected subcutaneously once weekly (FDA label).
It can be injected in the abdomen, thigh, or upper arm, on the same day each week, at any time of day, with or without food. Rotate injection sites. A missed dose can be taken within 4 days (96 hours); otherwise skip it and resume the regular schedule. Slow, patient titration is the single most effective way to limit nausea and other GI effects.
Mounjaro carries an FDA boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Tirzepatide caused thyroid C-cell tumors in rats; whether it does so in humans is unknown, and human relevance has not been determined (FDA label). It is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with a known serious hypersensitivity to tirzepatide (FDA label).
The most frequent side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, decreased appetite, indigestion, and abdominal pain (FDA label). In the diabetes trials, nausea affected up to roughly 1 in 5 patients (about 12–18% depending on dose), and these events were most common during dose escalation and generally eased over time.
Best suited for: adults with type 2 diabetes who need substantial A1C improvement, particularly those who also carry excess weight, since the weight and metabolic benefits are pronounced. It is a strong option for people inadequately controlled on metformin and for those with established cardiovascular disease who want a glucose-lowering agent with demonstrated cardiovascular safety.
Should avoid or use caution: anyone with a personal/family history of MTC or MEN 2 (absolute contraindication); people with type 1 diabetes; those with a history of pancreatitis or severe gastrointestinal disease (e.g., gastroparesis); and people who cannot reliably manage injections or tolerate GI side effects. People seeking the drug purely for weight loss should know the on-label, properly indicated product for that purpose is Zepbound, not Mounjaro — a distinction that matters for both clinical appropriateness and insurance coverage.
Mounjaro's list price is roughly $1,080 per 28-day supply (four pre-filled pens) across all dose strengths (Lilly). Actual out-of-pocket cost varies enormously:
Coverage is the central access barrier. Many commercial plans cover Mounjaro for type 2 diabetes, but prior authorization is common, and plans frequently exclude tirzepatide when prescribed for weight loss, which is one reason the brand distinction (Mounjaro vs. Zepbound) carries real financial weight. Lilly's self-pay vial program (LillyDirect) has lowered cash prices for the weight-management product Zepbound, but those self-pay prices are tied to Zepbound rather than to the Mounjaro diabetes brand. Always verify current pricing and your specific plan's coverage, as list prices, savings programs, and self-pay offers change frequently. Compounded "tirzepatide" sold by some online vendors is not FDA-approved as a finished product and is not the same as Mounjaro; the FDA has warned about quality and dosing risks with such products.
Mounjaro (tirzepatide) is one of the most effective glucose-lowering medications ever brought to market for type 2 diabetes, with the bonus of substantial weight loss and, as of 2025, confirmed cardiovascular safety in a high-risk population (NEJM). Its first-in-class dual GIP/GLP-1 mechanism translated into measurably better A1C and weight outcomes than a leading GLP-1 competitor in head-to-head testing (NEJM 2021). The trade-offs are real and should not be minimized: a boxed thyroid-tumor warning, frequent gastrointestinal side effects during titration, important contraindications and interactions, and a list price exceeding $1,000 a month that puts it out of reach for many without solid insurance coverage. For an adult with type 2 diabetes — especially one who also needs to lose weight or has heart disease — Mounjaro is a top-tier, evidence-backed choice when prescribed and monitored by a clinician. If the goal is weight loss alone, the correctly indicated product is Zepbound, and the decision should still run through a licensed prescriber rather than an unregulated online source.
*This article is for general education and is not medical advice. Mounjaro is a prescription medication; discuss your individual risks, benefits, and alternatives with a licensed healthcare professional.*
Mounjaro's active ingredient, tirzepatide, is a "dual agonist" that activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most older drugs in this class hit only GLP-1. By stimulating both, tirzepatide prompts the pancreas to release insulin when blood sugar is high, lowers the glucagon hormone that raises blood sugar, slows how fast the stomach empties, and reduces appetite. The net effect is better blood-sugar control and, as a downstream benefit, significant weight loss. A built-in fatty-acid chain lets it bind to blood albumin, giving it a long half-life so it only needs to be injected once a week.
Active ingredient: Tirzepatide
In SURPASS-2, an open-label 40-week head-to-head trial of 1,879 adults with type 2 diabetes published in the New England Journal of Medicine (2021), tirzepatide beat injectable semaglutide 1 mg. In the primary (treatment-regimen) analysis, the 15 mg dose lowered A1C by about 2.30 percentage points and reduced body weight by roughly 11.2 kg (about 12% from a baseline near 94 kg), and the 5 mg dose lowered A1C by about 2.01 points with about 7.6 kg lost — versus 1.86 points and 5.7 kg with semaglutide. (In the secondary on-treatment analysis, 15 mg figures were larger, about 2.46 points and 12.4 kg.) About 60% of participants on 15 mg hit a combined target of A1C 6.5% or lower plus at least 10% weight loss, compared with 22% on semaglutide. In the separate SURPASS-CVOT outcomes trial (about 13,300 patients with type 2 diabetes and established atherosclerotic heart disease, ~4-year median follow-up, published in NEJM in 2025), tirzepatide was non-inferior to dulaglutide for major adverse cardiovascular events (HR 0.92) and showed a 16% lower rate of all-cause death (HR 0.84), alongside greater A1C and weight reductions. These trials were in people with type 2 diabetes; your results may differ.
A realistic timeline of what Mounjaro users typically experience. Individual results vary; this is educational, not medical advice.
You begin once-weekly subcutaneous injections at 2.5 mg. This is a priming dose, not meant to be fully therapeutic; its job is to let your gut adjust. Many people notice reduced appetite and earlier fullness within the first doses, and GI side effects (nausea, constipation, or diarrhea) are most common now. Symptoms are usually mild-to-moderate and tend to be worst in this first month.
If the starter dose is tolerated, your prescriber typically raises you to 5 mg/week. Doses are then increased in 2.5 mg steps (7.5, 10, 12.5, up to a 15 mg max) no sooner than every 4 weeks, only as needed and as tolerated. Expect a temporary return of nausea or other GI effects for a few days after each increase; these usually ease as you stabilize.
In the SURMOUNT-1 weight-management trial, participants lost roughly 5% of body weight on average by about this point. Real results vary widely with dose, diet, activity, and individual response; some people see less, and slower responders can still catch up later. This is a common checkpoint for your clinician to review tolerance, weight, and (if you have diabetes) blood sugar.
As you reach and hold a maintenance dose, appetite suppression and weight loss generally continue at a steadier pace, and GI side effects are usually much milder once titration ends. For type 2 diabetes, meaningful A1C reductions were seen by about week 40 in the SURPASS trials. The average time to reach 5% weight loss across the trial was roughly 25 weeks, underscoring that progress is gradual.
Clinical trials measured peak average weight loss out to about 72 weeks (mean reductions ranged by dose in SURMOUNT-1, roughly 15% to over 20%). Your own result depends on dose reached, adherence, and lifestyle, and may be higher or lower. Many people are still losing or have plateaued near this point.
Obesity and type 2 diabetes are chronic conditions, so Mounjaro is generally used long-term. Stopping often leads to appetite returning and some weight regain. Continued use is paired with regular clinician follow-up to monitor dose, side effects, labs, and goals. This is a prescription medicine; all dosing and changes must be directed by your healthcare provider.
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These are usually mild to moderate, most pronounced when starting and after each dose increase, and tend to ease over days to weeks. Serious but less common risks include acute pancreatitis (severe, persistent stomach pain — seek care immediately), gallbladder problems and gallstones (more likely during rapid weight loss), severe low blood sugar especially when combined with insulin or sulfonylureas, kidney injury from dehydration due to vomiting or diarrhea, allergic reactions, and possible worsening of diabetic retinopathy. The boxed warning concerns thyroid C-cell tumors seen in rodents; whether this risk applies to humans is unknown, so watch for a neck lump, hoarseness, trouble swallowing, or persistent shortness of breath and tell your doctor. Report any severe or persistent symptoms to your prescriber.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $1349/mo from Eli Lilly.
As of 2026, Mounjaro's US list price is roughly $1,000-$1,080 for a one-month (four-pen) supply, with cash/retail prices often quoted between about $995 and $1,300 depending on pharmacy. With commercial insurance that covers Mounjaro for diabetes, Eli Lilly's Mounjaro Savings Card can drop the cost to as little as $25 per month (subject to a per-fill and annual cap). If you have commercial insurance that does NOT cover it, the savings card may bring it to as low as about $499/month. Federal rules bar manufacturer copay cards for people on Medicare, Medicaid, TRICARE, or VA. Medicare Part D may cover Mounjaro for type 2 diabetes (with formulary tier and prior-authorization rules) but does not cover GLP-1 drugs for weight loss. Off-label use for weight loss is increasingly denied by insurers. Confirm current pricing and your own coverage before starting.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If you have type 2 diabetes and commercial insurance covers it, Mounjaro delivers category-leading A1C and weight results with a side-effect profile that is mostly gastrointestinal and usually manageable. If you want it purely for weight loss, expect coverage hurdles and consider Zepbound instead. Budget for nausea early on, a slow titration over several months, and a high list price that the savings card only partly offsets. Discuss your full medical history with a clinician before starting.
No. Mounjaro is FDA-approved only to improve blood sugar in type 2 diabetes (in adults and children 10 and older). The identical drug (tirzepatide) is sold as Zepbound for chronic weight management and obstructive sleep apnea. Doctors can prescribe Mounjaro off-label for weight loss, but insurers increasingly deny coverage for that use.
In the SURPASS-2 trial of adults with type 2 diabetes, those on the highest 15 mg dose lost about 11.2 kg (roughly 12% of body weight) over 40 weeks in the primary analysis, while those on 5 mg lost about 7.6 kg; the comparator semaglutide group lost about 5.7 kg. Individual results vary and depend on dose, diet, and exercise.
They are the same active drug, tirzepatide, made by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. The main practical differences are the FDA-approved use and how insurance covers each one.
The US list price is roughly $1,000-$1,080 per month. With commercial insurance that covers it, Lilly's savings card can lower the cost to as little as $25/month; if your plan doesn't cover it, the card may bring it to as low as about $499/month. Government insurance (Medicare, Medicaid, TRICARE, VA) cannot use the copay card.
It starts lowering blood sugar within the first week or two, and appetite often drops within days. Meaningful weight and A1C changes typically build over several weeks, with fuller benefits usually appearing over a few months as the dose is gradually titrated up.
The most common are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain. They are usually mild to moderate, worst when starting or increasing the dose, and tend to improve over time. Seek care for severe, persistent stomach pain, which can signal pancreatitis.
Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use it. It's also not for type 1 diabetes, and caution is advised with a history of pancreatitis, gallbladder disease, severe GI conditions, diabetic retinopathy, or during pregnancy. Your prescriber makes the final call.
If it has been 4 days (96 hours) or less since your missed dose, take it as soon as you remember. If more than 4 days have passed, skip it and take your next dose on the regular scheduled day. Never take two doses at once. When in doubt, ask your prescriber or pharmacist.
Alcohol doesn't directly interact with Mounjaro, but it can worsen GI side effects, raise the risk of low blood sugar (especially with diabetes medications), and make weight management harder. Many providers advise limiting alcohol; discuss your situation with your care team.
No. The FDA removed Mounjaro/tirzepatide from its drug shortage list in late 2024 (a decision it upheld in December 2024), and as of 2026 all dose strengths are generally available, though occasional local pharmacy stock gaps can still occur.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Mounjaro — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
The maker of Mounjaro runs a commercial-insurance savings program that can lower your copay. See the official Mounjaro savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.